Good morning, everyone. Damian Garde here, filling in for Ed Silverman at the start of yet another working week. The holidays are just within sight, beyond the routine of deadlines, and meetings, and internal debates over whether it’s OK to leave your camera off this one time. Here to get your week in motion is that regular menu of tidbits. And, as always, if you hear anything interesting out there, please let us know. …
An expert committee that advises the Centers for Disease Control and Prevention on vaccines voted unanimously to recommend Covid-19 booster-shot eligibility be thrown open to all adults 18 and older, STAT informs us. The group also voted to lower the age for adults who should be urged to get a booster. CDC Director Rochelle Walensky quickly signed off on the changes. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2021/11/22/cdc-covid19-boosters-novartis-pfizer-biontech/
